Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.78 |
| ▸ | LOXL2 | Q9Y4K0 | 7/20 | 0.61 |
| ▸ | ABAT | P80404 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | F11 | P03951 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828 | 0.89 | HRH3 (0.79) | HRH3TAAR1LOXL2ABATADRB2 | |
| SCHEMBL131842 | 0.88 | TAAR1 (1.00) | HRH3TAAR1LOXL2ADRB2CYP2A6 | |
| SCHEMBL3787138 | 0.88 | LOXL2 (0.83) | HRH3TAAR1LOXL2ABATADRB2 | |
| SCHEMBL22291708 | 0.88 | TAAR1 (1.00) | HRH3TAAR1LOXL2ADRB2CYP2A6 | |
| SCHEMBL22202237 | 0.88 | TAAR1 (1.00) | HRH3TAAR1LOXL2ADRB2CYP2A6 | |
| SCHEMBL16253356 | 0.86 | HRH3 (0.74) | HRH3TAAR1LOXL2ABATADRB2 | |
| SCHEMBL4415525 | 0.86 | LOXL2 (0.84) | HRH3TAAR1LOXL2ADRB2CYP2A6 | |
| Hydrochloric Acid SCHEMBL7921699 | 0.86 | TAAR1 (0.95) | HRH3TAAR1LOXL2ADRB2CYP2A6 | |
| SCHEMBL13814906 | 0.86 | HRH3 (0.74) | HRH3TAAR1LOXL2ABATADRB2 | |
| SCHEMBL2571691 | 0.86 | ABAT (0.84) | HRH3TAAR1LOXL2ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778299-A4 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INT BV (NL) | 2009-08-26 | — | — | EP | claimed |
| EP-1778299-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-02 | — | — | EP | claimed |
| WO-2006096207-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2006-09-14 | — | — | WO | claimed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | claimed |
| US-20230371289-A1 | IMAGING DEVICE | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2023-11-16 | — | — | US | disclosed |
| US-10809574-B2 | Liquid crystal alignment agent, liquid crystal alignment film, and liquid crystal display device | SHARP KABUSHIKI KAISHA (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20190233731-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2019-08-01 | — | — | US | disclosed |
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-8003750-B2 | Thermosetting composition | HUNTSMAN INTERNATIONAL LLC (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1199333-A1 | RESIN COMPOSITION CONTAINING CRYSTALLINE POLYIMIDE | TEIJIN LIMITED (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-0872504-A1 | CURABLE EPOXY RESIN COMPOSITION WHICH GIVES FLEXIBLE CURED ARTICLE | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1998-10-21 | — | — | EP | disclosed |
| EP-0870790-A1 | CURABLE EPOXY RESIN COMPOSITION | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1998-10-14 | — | — | EP | disclosed |
| EP-0241133-B1 | Polymaleimide compound and a composition containing the same | ASAHI CHEMICAL IND (JP) | 1994-08-03 | — | — | EP | disclosed |
| US-4761460-A | SOLUBLE IN LOW-BOILING SOLVENTS, CURABLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-08-02 | — | — | US | disclosed |
| EP-0241133-A2 | Polymaleimide compound and a composition containing the same | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-10-14 | — | — | EP | disclosed |
| US-4231789-A | APPLYING AN ALKYLENEDIAMINE | OKII MITSUYOSHI | 1980-11-04 | — | — | US | disclosed |
| US-3996201-A | MOLDING | CIBA-GEIGY CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | HRH3 4808/4885TAAR1 4493/4885LOXL2 2437/4885 |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | LDHB, FPGS, MTHFD2 | HRH3 2716/4885TAAR1 4205/4885LOXL2 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.